Does hormonal birth control raise cancer risk?

The IARC classifies substances by the strength of evidence that they cause cancer in humans. Group 1 means "sufficient evidence of carcinogenicity" -- the highest classification. Other Group 1 carcinogens include:

• Tobacco smoking
• Alcohol consumption
• Asbestos
• Benzene
• Formaldehyde
• Processed meat
• Combined estrogen-progestogen menopausal therapy (HRT)

Combined oral contraceptives joined this list in 2005¹. The IARC working group reviewed over 100 epidemiological studies and concluded that combined hormonal contraceptives cause an increased risk of breast cancer, cervical cancer, and hepatocellular (liver) cancer.

The classification doesn't mean every user will get cancer -- the same is true of tobacco. It means the causal link is established beyond reasonable scientific dispute.

The Cancers Linked to Hormonal Birth Control

Breast Cancer

The 2017 Mørch study in the New England Journal of Medicine followed 1.8 million Danish women for an average of 10.9 years and found⁴:

• Current and recent users of any hormonal contraception had a 20% higher relative risk of breast cancer
• Risk rose to 38% higher after more than 10 years of use
• The increased risk applied to modern low-dose pills and the levonorgestrel IUD -- not just older high-dose formulations
• Risk declined after stopping but remained elevated for several years

Earlier studies sometimes found smaller effects, partly because they used older formulations with confounded data. The Mørch (2017) data confirmed that the move to lower doses did not eliminate the breast cancer signal -- it persists in contemporary formulations, including the hormonal IUD often marketed as having minimal systemic effects⁴.

Cervical Cancer

The largest meta-analysis to date pooled individual data from 24 studies covering over 16,000 women with cervical cancer and 35,000 controls³. Findings:

• Five or more years of combined OC use roughly doubled cervical cancer risk in women infected with HPV
• Risk increased with longer duration of use
• Risk declined after stopping and returned to near-baseline within about 10 years

The Smith (2003) Lancet systematic review reached a similar conclusion: long-term combined OC use is a cofactor that promotes progression from HPV infection to cervical cancer². The mechanism appears to involve hormonal effects on cervical tissue that allow HPV to persist and replicate. Since nearly all sexually active women are exposed to HPV at some point, the OC-HPV interaction is not a niche concern.

Liver Tumors

Combined oral contraceptives are an established cause of hepatocellular adenoma -- a benign liver tumor that, while non-cancerous, can grow large enough to rupture and bleed into the abdomen. Risk increases with duration of use and is highest with older high-dose formulations, but cases continue to occur with modern pills.

Combined OCs also modestly increase risk of hepatocellular carcinoma (liver cancer), particularly in women without underlying viral hepatitis. Liver cancer is rare in young women, so the absolute risk is small -- but it is part of the IARC's basis for the Group 1 classification¹.

What's Reduced (the Honest Trade-Off)

The story isn't all one-directional. Combined hormonal contraception clearly reduces risk of:

• Ovarian cancer: Roughly 50% reduction with long-term use, persisting for decades after stopping
• Endometrial cancer: Roughly 50% reduction with long-term use
• Colorectal cancer: Modest reduction (~15-20%)

These are real benefits and deserve weight in any individual decision. The point isn't that hormonal contraception only causes cancer -- it's that the cancer profile is shifted, with breast, cervical, and liver cancer up and ovarian, endometrial, and colorectal cancer down. Whether that trade-off is worth it depends on a woman's family history, age, reproductive plans, and competing risks.

Beyond Cancer: Other Documented Disease Links

The carcinogen classification gets the most attention here, but the disease links don't stop at cancer.

Cardiovascular Disease

The Lidegaard (2012) NEJM study followed 1.6 million Danish women and found⁵:

• Combined oral contraceptive users had a roughly 1.5 to 2-fold increased risk of ischemic stroke
• Risk of myocardial infarction was elevated in a similar range
• Risk varied by progestin and estrogen dose, with newer formulations not protective

This is on top of the well-established 3-4 fold increased risk of venous thromboembolism -- clots in the deep veins or lungs⁶. For young, healthy, non-smoking women, absolute risk remains low. For women with hypertension, smoking history, migraine with aura, or family history of clotting, the absolute risk is materially higher and frequently undisclosed at prescription.

Inflammatory Bowel Disease (IBD)

Multiple cohort studies and meta-analyses have linked hormonal contraceptive use to a 30-50% increased risk of Crohn's disease and ulcerative colitis. The signal is strongest in current users and partially attenuates after stopping. Proposed mechanisms include estrogen effects on gut barrier function, immune signaling, and disruption of the gut microbiome.

Gallbladder Disease

Combined oral contraceptives modestly increase risk of gallbladder disease and gallstones, particularly during the first year of use. Estrogens raise cholesterol saturation in bile, which promotes stone formation.

Autoimmune Conditions

Hormonal contraception has been associated with elevated risk of several autoimmune conditions in observational studies:

• Lupus (SLE): Modest increased risk, particularly in women with genetic predisposition; estrogen-containing methods have been the larger concern
• Multiple sclerosis: Some cohorts report a modest increase in incidence
• Rheumatoid arthritis: Findings mixed; current use may transiently reduce flares while long-term effects are debated

The relationship is complex because sex hormones genuinely modulate immune function -- they don't just suppress or activate it across the board.

Mood and Mental Health

Covered in detail in the side effects section, but worth recapping in this context: the Skovlund (2016) cohort of over a million women found a 23% increased risk of antidepressant prescription with combined pills and an 80% increase in adolescents⁷. The 2018 follow-up found roughly doubled risk of suicide attempts. Mental health is increasingly understood as part of the disease burden of hormonal contraception, not a separate "side effect" to be footnoted.

Microbiome Disruption

Hormonal contraceptives alter the gut microbiome, the vaginal microbiome, and intestinal permeability. The clinical consequences are still being mapped but appear to overlap with the IBD signal and contribute to dysbiosis-related conditions.

The IARC's 2005 Group 1 classification of combined estrogen-progestogen contraceptives is not a fringe finding¹. It is the consensus position of the World Health Organization's specialized cancer agency, based on a comprehensive review of the human evidence by an international working group. Public communication of this classification has been minimal -- partly because the absolute cancer risk increase per individual per year is small, partly because the protective effects on ovarian and endometrial cancer get more attention -- but the classification has stood for two decades and has been reaffirmed in subsequent IARC monographs.

The Mørch (2017) NEJM cohort is the strongest evidence that the breast cancer signal applies to current formulations, including the levonorgestrel IUD that is often marketed as having minimal systemic effects⁴. A 20% relative risk increase for current users, rising to 38% with long use, is small in any single year but compounds over a reproductive lifetime that often includes 15-25 years of cumulative use.

The cervical cancer evidence is among the most robust^2,3. The International Collaboration of Epidemiological Studies pooled data from 16,573 women with cervical cancer and 35,509 controls -- a sample size that resolves any remaining uncertainty about the link, the duration-response, and the reversibility after stopping³. The mechanism (hormonal cofactor for HPV persistence) is biologically coherent.

The Lidegaard (2012) NEJM stroke and MI data, combined with Vinogradova (2015) on VTE, establish that combined hormonal contraception elevates cardiovascular risk across multiple endpoints, not just clots^5,6. For most healthy young women, absolute risk remains small. For women with even one of the standard cardiovascular risk factors -- hypertension, smoking, migraine with aura, family history of clotting -- the calculus shifts substantially, and the level of pre-prescription screening for these factors in routine practice is often inadequate.

The non-cancer disease links -- IBD, gallbladder disease, autoimmune conditions, mood disorders, microbiome disruption -- are individually less discussed than they should be given the size of effect in the most rigorous studies.

The bottom line: Hormonal birth control is classified as a carcinogen by the World Health Organization, and the case for that classification is solid. It also has documented links to cardiovascular disease, IBD, gallbladder disease, autoimmune conditions, and mood disorders. None of this means the medication is illegitimate or that women shouldn't have access to it. It means the conversation about whether to take it -- and which form, and for how long -- deserves to include the full risk profile, weighed against pregnancy prevention and the legitimate condition-specific reasons (severe endometriosis, debilitating cycles, specific medical situations) that many women have for using it. Informed consent requires actually being informed.